SCHEMBL4694569

SCHEMBL4694569

CCOC(=O)c1cc(N)ccc1Oc1cc(F)cc(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
GAA P10253 4/20 0.46
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 3/20 0.46
RAB9A P51151 3/20 0.46
LMNA P02545 2/20 0.46
ALOX15 P16050 2/20 0.46
NPC1 O15118 2/20 0.46
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 1/20 0.44
MAOA P21397 1/20 0.44
TSHR P16473 2/20 0.43
HPGD P15428 1/20 0.40
EPAS1 Q99814 1/20 0.40
CYP2D6 P10635 1/20 0.39
SCN1A P35498 1/20 0.39
SCN2A Q99250 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4696137 0.85 LMNA (0.42) SMN1; SMN2GAAALDH1A1HSD17B10MEN1
SCHEMBL2749972 0.84 PPARG (0.47) SMN1; SMN2GAAALDH1A1HSD17B10MEN1
SCHEMBL2750155 0.84 ALDH1A1 (0.51) SMN1; SMN2GAAALDH1A1HSD17B10MEN1
SCHEMBL4697820 0.80 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL6588826 0.79 LMNA (0.53) SMN1; SMN2GAAALDH1A1HSD17B10MEN1
SCHEMBL1671606 0.79 LMNA (0.53) SMN1; SMN2GAAALDH1A1HSD17B10MEN1
SCHEMBL4694564 0.78 PPARG (0.44) SMN1; SMN2GAAALDH1A1HSD17B10MEN1
SCHEMBL1496445 0.77 LMNA (0.54) SMN1; SMN2GAAALDH1A1HSD17B10MEN1
SCHEMBL13076753 0.77 LMNA (0.47) SMN1; SMN2GAAALDH1A1HSD17B10MEN1
SCHEMBL4696258 0.77 PPARG (0.63) CYP3A4PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1053227-B1 PPAR-GAMMA MODULATORS AMGEN INC (US) 2008-11-05 EP disclosed
US-7439242-B2 PPARγ modulators AMGEN INC. (US) 2008-10-21 US disclosed
US-6620827-B2 Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents TULARIK INC. 2003-09-16 US disclosed
US-20030088103-A1 PPARgamma modulators TULARIK INC. (US) 2003-05-08 US disclosed
US-20010027200-A1 PPARgamma modulators TULARIK INC. 2001-10-04 US disclosed
US-6200995-B1 PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY TULARIK INC. 2001-03-13 US disclosed
EP-1053227-A1 PPAR-GAMMA MODULATORS TULARIK, INC. (US) 2000-11-22 EP disclosed
WO-1999038845-A1 PPAR-GAMMA MODULATORS TULARIK INC. (US) 1999-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030088103-A1 PPARgamma modulators PPARG, PPARA, PPARD SMN1; SMN2 3973/4885GAA 782/4885ALDH1A1 1959/4885
US-20010027200-A1 PPARgamma modulators PPARG, PPARA, PPARD SMN1; SMN2 3973/4885GAA 782/4885ALDH1A1 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.